化合物Tegoprazan T17030

Product Introduction
Bioactivity


英文名: Tegoprazan

描述: Tegoprazan 是一种口服有效的、高选择性胃 H+/K+-ATP 酶 (H+/K+-ATPase) 抑制剂，能够控制胃酸分泌和运动，在体外检测的对猪、犬、人的 H+/K+-ATP 酶的 IC50为0.29-0.52 μM。

体外活性: Tegoprazan inhibits gastric H+/K+-ATPase in a potassium-competitive and reversible manner and it also inhibits porcine, canine, and human H+/K+-ATPase activity. Tegoprazan (3 μM) inhibits 86% of H+/K+-ATPase activity, whereas the inhibition is decreased to 34% after the dilution of Tegoprazan concentration to 0.15 μM [1].

体内活性: Tegoprazan (1.0-3.0 mg/kg, p.o.) reverses the pentagastrin-induced acidified gastric pH to the neutral range. Tegoprazan (1.0 mg/kg, p.o.) effectively and fully inhibits histamine-induced gastric acid secretion in dogs. Tegoprazan (3 mg/kg, p.o.) immediately evokes a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 22.5 mg/mL (58.08 mM)


关键字: pentagastrin | Proton Pump | acid | Tegoprazan | gastric | secretion | inhibit | Inhibitor

相关产品: Vonoprazan fumarate | Strophanthidin | 3-Hydroxybakuchiol | Esomeprazole Magnesium | Suloctidil | Cabraleadiol | Dicirenone | Retusin | Blebbistatin | Marinobufogenin

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Inhibitor Library | Highly Selective Inhibitor Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Anti-Infection Compound Library

化合物Tegoprazan T17030信息由TargetMol中国为您提供，如您想了解更多关于化合物Tegoprazan T17030报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途